

Production of Capsular Polysaccharide of *Streptococcus pneumoniae* Type 14 and Its Purification by Affinity Chromatography

NORMA SUÁREZ,¹ LAURA FRANCO FRAGUAS,² ESTHER TEXEIRA,³ HUGO MASSALDI,³
FRANCISCO BATISTA-VIERA,² AND FERNANDO FERREIRA^{1*}

Laboratorio de Carbohidratos y Glicoconjugados, Departamento de Química Orgánica, Facultad de Química,¹ and Departamento de Desarrollo y Producción, Facultad de Medicina,³ Instituto de Higiene, C.P. 11600, and Facultad de Química, Cátedra de Bioquímica, CC 1157,² Montevideo, Uruguay

Received 23 December 1999/Accepted 20 October 2000

We describe a rapid and efficient method for producing the capsular polysaccharide of *Streptococcus pneumoniae* by fermentation on tryptic soy broth and purification of this compound by using immobilized soybean lectin as an affinity adsorbent. In principle, the same strategy can be used to produce purified capsular polysaccharides from other streptococcal serotypes by selecting the appropriate lectin adsorbents.

Streptococcus pneumoniae produces capsular polysaccharides that have been found to be important in infective processes, such as pneumonia, meningitis, otitis, and several other infectious diseases that cause considerable morbidity and mortality in children in most countries of the world (11). These polysaccharides are type specific and contain the main antigenic determinant of *S. pneumoniae*. The bacterium presents a multiplicity of serotypes, and serotype 14 is the predominant serotype in South American countries (2).

Chemical studies have shown that there is a relationship between capsular structure and immunological specificity, and both aspects of the serotype 14 capsular polysaccharide (CPS-14) have been extensively studied (3, 4). This polysaccharide is composed of a tetrasaccharide repeating unit containing D-glucose, N-acetyl-D-glucosamine, and D-galactose (6), as shown in Fig. 1. It is one of the few neutral capsular polysaccharides produced by pneumococcus strains, and several patents (1a, 3a) have been issued for its preparation and purification. Our purification procedure is based on the use of immobilized lectins. Soybean (*Glycine max*) lectin, which is specific for D-galactose and N-acetyl-D-galactosamine, can recognize the galactosyl residues present in the repeating unit of CPS-14 (8). Purification of CPS-14 by affinity chromatography as described here consists of a one-step procedure in which a commercial immobilized soybean lectin is used.

Production and purification of CPS-14. CPS-14 was prepared from *S. pneumoniae* strains obtained from The National Centre for Streptococcus (Alberta, Canada) as described by Lund and Henrichsen (7) in 5-liter flasks containing 2 liters of tryptic soy broth (Difco Laboratories, Detroit, Mich.) and incubated at 37°C for 18 to 24 h. Growth was stopped by adding formaldehyde to a final concentration of 0.2% (wt/vol); the cells were lysed with sodium deoxycholate (0.1%, wt/vol) and

then centrifuged. The supernatant was concentrated by ultrafiltration (using a hollow fiber cartridge with a molecular mass cutoff of 10 kDa) to 1/10 the original volume, and it was extensively dialyzed against distilled water and lyophilized.

In a typical experiment, 165 mg of lyophilized powder was suspended in 5 ml of 50 mM sodium phosphate buffer (pH 7.4) containing 0.15 M NaCl (PBS buffer). The suspension was centrifuged at 4°C for 15 min at 4,000 × g. A 4-ml portion of the clear supernatant was applied to a column packed with 2 ml of commercial soybean lectin-agarose (Sigma Chemical Co., St. Louis, Mo.). According to the manufacturer, the ligand content was approximately 2 mg of lectin per ml of packed gel. Nonbound material was recycled three times, and the column was then washed with 16 ml of PBS buffer. Elution was performed with 0.1 M D-galactose in PBS buffer. Two 4-ml fractions were collected, and each fraction was dialyzed against distilled water or gel filtered by using prepacked PD-10 columns (Pharmacia Amersham, Uppsala, Sweden) with distilled water and finally lyophilized. For a small laboratory bench scale up of the procedure, a column was packed with 9.0 ml of soybean lectin-agarose and the protocol described above was used with appropriately scaled volumes.

Specific latex reagent. Rabbits were immunized with serotype 14 aldehyde-inactivated *S. pneumoniae* bacterial cells by using the immunization protocol of Lund and Henrichsen (7). Peripheral blood was collected, and the immunoglobulin fraction was purified from the serum by salt precipitation with 30% saturated ammonium sulfate. To avoid cross-reactions with the C polysaccharide produced by all serotypes, anti-C antibodies were eliminated by adsorption with a suspension of inactivated cells of a noncapsulated rugose C-mutant *S. pneumoniae* strain. The antisera were adsorbed onto latex reagent by the method of Battistoni (1). Agglutination of the samples was quantified by a twofold serial dilution assay. The titer was defined as the reciprocal of the highest dilution able to produce visible agglutination.

Protein content. The protein content was determined both spectrophotometrically by using the relationship between ab-

* Corresponding author. Mailing address: Laboratorio de Carbohidratos y Glicoconjugados, Departamento de Desarrollo y Producción, Instituto de Higiene, C.P. 11600, Av. A. Navarro 3051, Montevideo, Uruguay. Phone: (598) 2 4871288. Fax: (598) 2 4873073. E-mail: fferreir@bilbo.edu.uy.

was 0.15% (wt/wt) (spectrophotometric method) or zero (bichinchonic acid method). The results for the eluted material in Table 1 are the results for the first elution fraction. The polysaccharide content of the second elution fraction was very low, as indicated by the latex technique (titer, 64). Furthermore, the protein content was 4.5%, and so the second elution fraction was discarded. The maximum capacity of the column was found to be approximately 1.5 mg of polysaccharide per ml of soybean lectin-agarose-packed gel (Table 1).

The process was scaled up to a 9.0-ml packed gel column. In this case the capacity of the column was 1.2 mg of polysaccharide per ml of packed gel, and after three cycles the capacity was 1.1 mg of polysaccharide per ml of packed gel.

Identity and quality of the product. The polysaccharide obtained reacted positively with CPS-14-specific latex reagent, giving a high titer, as indicated in Table 1. Sugar analysis of the product revealed the presence of D-glucose, N-acetyl-D-glucosamine, and D-galactose at relative proportions of 1:1:2, which corresponded to the reported composition of the polysaccharide (6). The ¹H-NMR spectra (Fig. 2) showed the tetrasaccharide repetitive unit having all of the monosaccharides in the anomeric β-configuration and the presence of an N-acetyl group, as expected. No leakage of lectin from the column was observed, as indicated by negative hemagglutination (9) performed with the eluted material.

The one-step purification procedure described here is easy to perform and faster than traditional multistep methods that include fractional precipitation, protease and DNase treatments, and/or ion-exchange chromatography, among other procedures (1a, 3a). In contrast, a good yield of high-purity CPS-14 is produced by our one-step method, and our procedure may be easily scaled up.

We are indebted to J. Battistoni for his valuable advice.

We are grateful for financial support from the Program for Devel-

opment of Basic Sciences, the Pan American Health Organisation, the International Program in the Chemical Sciences (project URU:02), the International Foundation for Science (project F-2834-1), and the Organisation for the Prohibition of Chemical Weapons.

REFERENCES

1. **Battistoni, J.** 1998. Reactivos de Inmunodiagnóstico por aglutinación de partículas de látex. Tesis de Magister. Facultad de Química, Montevideo, Uruguay.
- 1a. **Berri-Balzac Sociéte.** 1982. Procédé d'obtention de polysides capsulaires, polysides capsulaires ainsi obtenus et leur application à la préparation de vaccins. European patent B1 0071515.
2. **Hortal, M., G. Algorta, I. Bianchi, G. Borthagaray, I. Cestau, T. Camou, M. Castro, M. de los Santos, R. Diez, L. Dell'Acqua, A. Galiana, A. Giordano, P. Giordano, G. López-Ghemi, N. Milanese, G. Mogdasy, R. Palacio, W. Pedreira, A. Pisano, and L. Pivel.** 1997. Capsular type distribution and susceptibility to antibiotics of *Streptococcus pneumoniae* clinical-strains isolated from Uruguayan children with systemic infections. *Microb. Drug Resist.* **3**:159–163.
3. **How, M. J., J. S. Brimacombe, and M. Stacey.** 1964. The pneumococcal polysaccharides. *Adv. Carbohydr. Chem.* **19**:303–358.
- 3a. **Institut Merieux.** 1980. Procédé de purification de polysides de *Streptococcus pneumoniae* et vaccin à base de polysides ainsi purifiés. Brevet Belge, déposée par la société anonyme dite: Institut Merieux no. 8026320. European patent B74899.
4. **Larm, O., and B. Lindberg.** 1976. The pneumococcal polysaccharides: a re-examination. *Adv. Carbohydr. Chem. Biochem.* **33**:295–322.
5. **Layne, E.** 1957. Spectrophotometric and turbidimetric methods for measuring proteins. *Methods Enzymol.* **3**:447–454.
6. **Lindberg, B., J. Lönngren, and D. A. Powell.** 1977. Structural studies on the specific type 14 pneumococcal polysaccharide. *Carbohydr. Res.* **58**:177–186.
7. **Lund, E., and J. Henrichsen.** 1978. Laboratory diagnosis, serology and epidemiology of *Streptococcus pneumoniae*. *Methods Microbiol.* **12**:242–261.
8. **Mandal, D. K., E. Nieves, L. Bhattacharyya, G. A. Orr, J. Roboz, Q. Yu, and C. Brewer.** 1994. Purification and characterisation of three isolectins of soybean agglutinin. *Eur. J. Biochem.* **221**:547–553.
9. **Nowak, T. P., P. L. Haywood, and S. H. Barondes.** 1976. Developmentally regulated lectin in embryonic chick muscle and a myogenic cell line. *Biochem. Biophys. Res. Commun.* **68**:650–657.
10. **Smith, P. K., R. I. Khron, G. F. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, and D. C. Klent.** 1985. Measurement of protein using the bichinchonic acid. *Anal. Biochem.* **150**:76–85.
11. **World Health Organisation.** 1996. Key vaccines under development, p. 101. *IN State of the world's vaccines and immunisation.* UNICEF, New York, N.Y.